DNA-Guided heart therapy could prevent thousands of heart attacks

NCT ID NCT03783351

Ongoing Disease control Sponsor: Beijing Anzhen Hospital Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study looked at whether using a person's genetic information to choose their blood thinner medication after getting a heart stent can reduce the risk of heart attacks, strokes, and death. About 4,000 people with heart disease were given either clopidogrel or ticagrelor based on their CYP2C19 gene type. The goal was to see if this personalized approach is safer and more effective than standard care.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ACUTE CORONARY SYNDROME are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

acute coronary syndrome Angina, Stable coronary artery disorder intermediate coronary syndrome

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ACUTE CORONARY SYNDROME ANGINA (STABLE) DRUG-ELUTING STENTS GENOTYPE

Contacts and locations

Locations

Beijing Anzhen Hospital

Beijing, Beijing Municipality, 100029, China
Beijing Chaoyang Hospital

Beijing, Beijing Municipality, 100000, China
Beijing Friendship Hospital

Beijing, Beijing Municipality, 100050, China
Beijing LuHe Hospital

Beijing, Beijing Municipality, 101199, China
Beijing Tong Ren Hospital

Beijing, Beijing Municipality, 100730, China
Beijing Tsinghua Changgung Hospital

Beijing, Beijing Municipality, 102218, China
China-Japan Friendship Hospital

Beijing, Beijing Municipality, China
Fuwai Hospital Chinese Academy of Medical Sciences

Beijing, Beijing Municipality, 100037, China
Peking Union Medical College Hospital

Beijing, Beijing Municipality, 100032, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.